It will be good coads. I was calling $1.2 million in sales...

It will be good coads. I was calling $1.2 million in sales (recognised revenue to go on top of that of course) but I am now thinking $1.3 given the Henry Schein, ACE Southern and Bio Horizons marketing of Strait. This is the first quarter that will fully include sales from the first two and we already had very strong growth on twelve months of Bio Horizons sales which is likely to go exponential in growth on its own as market placement consolidates.

Its coming off such a small base, it could easily be $1.5 mill, but I am calling $1.3 million based on past growth and other factors.

People not used to DCF analysis should go look at Veritas again, they were calling $4.6 million in revenues for FY24, OCC reported $1.8 for 1Q FY24 already of course.

https://orthocell.com/wp-content/uploads/2023/04/Veritas-Note-OCC_180423.pdf

I did say before Veritas didn't do a great hob on R&D tax offsets so quite understate cash balances as already shown by actual OCC figures....but people can jiggle it and other figures around to their own liking. Handy blueprint....